GCP
AMLX icon

GSA Capital Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

GSA Capital Partners’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-36,758
Closed -$444K – 1684
2025
Q4 		$444K Sell
36,758
-15,349
-29% -$208K 0.04% 902
2025
Q3 		$708K Sell
52,107
-118,426
-69% -$1.11M 0.06% 615
2025
Q2 		$1.09M Buy
170,533
+147,448
+639% +$717K 0.08% 401
2025
Q1 		$82K Buy
23,085
+12,446
+117% +$44.3K 0.01% 1520
2024
Q4 		$40K Buy
+10,639
New +$50.1K ﹤0.01% 1541
2024
Q2 		– Sell
-79,652
Closed -$226K – 1596
2024
Q1 		$226K Sell
79,652
-52,525
-40% -$687K 0.02% 1352
2023
Q4 		$1.95M Buy
132,177
+89,742
+211% +$1.38M 0.16% 128
2023
Q3 		$777K Buy
42,435
+28,431
+203% +$601K 0.07% 535
2023
Q2 		$302K Buy
14,004
+5,895
+73% +$159K 0.03% 1046
2023
Q1 		$238K Buy
+8,109
New +$282K 0.02% 1160

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

GSA Capital Partners's AMLX Position: Q1 2026 in Review

GSA Capital Partners sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 36,758 shares — an estimated $444K sold.

GSA Capital Partners first reported a position in AMLX in Q1 2023 and held it in 10 quarters. The position peaked at $1.95M in Q4 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • GSA Capital Partners reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 36,758 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $444K.
  • GSA Capital Partners first reported a position in Amylyx Pharmaceuticals in Q1 2023 and held it in 10 quarters.
  • GSA Capital Partners's Amylyx Pharmaceuticals position peaked at $1.95M in Q4 2023.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.